HEPLISAV-B achieved preliminary net product revenue of $268M for the full year 2024, an increase of 26% compared to $213M for the full year 2023. FY24 revenue consensus $276.94M
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks